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Objectives: We studied gp41 mutations associated with failing enfuvirtide salvage therapy.
Methods: This multicentre study involved patients with HIV-1 plasma viral load (pVL) > 5000 copies/mL
after at least 3 months of uninterrupted enfuvirtide therapy and with plasma samples available at
inclusion (T0), at initial enfuvirtide failure (T1) and at last follow-up visit during continued failing enfu-
virtide therapy (T2). The HR-1 and HR-2 domains of the gp41 gene were sequenced at T0, T1 and T2.
Results: Ninety-nine patients were enrolled. At baseline, the median pVL and CD4 cell count were
5.1 log copies/mL and 72 cells/mm3, respectively. Based on the ANRS Resistance Group algorithm, the
proportion of patients harbouring viruses with enfuvirtide resistance mutations increased significantly
between T0 and T1. In the HR-1 domain, the V38A/M, Q40H, N42T, N43D and L45M mutations were
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selected (P < 0.02). In the HR-2 domain, no mutations were significantly selected during the follow-up.
None of the mutations was associated with a CD4 cell count increment.
Conclusions: Mutations selected during failing enfuvirtide salvage therapy are mainly located in the
HR-1 domain of the gp41 gene, between codons 38 and 45. No mutations were associated with an
increase in the CD4 cell count.
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Introduction
Enfuvirtide-resistant viral populations have been found to bear
mutations in the highly conserved three amino acid motif at
positions 36–45 of the HR-1 domain of the gp41 gene. Other
studies have also shown mutations in a wider region of HR-1
(amino acids 36–45). The aim of this study was to identify
mutations in the HR-1 and HR-2 domains of the HIV-1 gp41
protein in heavily treated patients in whom enfuvirtide-
containing salvage therapy was initially effective and then
failed.
Patients and methods
This multicentre study involved 99 heavily treated enfuvirtide-naive
HIV-1-infected patients from 15 HIV/AIDS centres. They all
experienced virological failure while receiving an enfuvirtide-
containing salvage regimen with plasma viral load .5000 copies/mL
after at least 3 months on enfuvirtide combination therapy. Plasma
samples were available at baseline (T0), at the time of virological
failure (T1) and, in 55 cases, during continued failing enfuvirtide
therapy (T2). All patients gave written informed consent, and the
study was approved by the Comite´ Consultatif de Traitement de
l’Information dans la Recherche Scientifique et Me´dicale and the
Commission Nationale Informatique et Liberte´s.
Population-based sequencing of the HR-1 and HR-2 domains of
the gp41 gene was performed at T0, T1 and T2 by using the ANRS
protocol (www.hivfrenchresistance.org). Enfuvirtide mutations were
identified from the IAS-USA 2006 expert list of mutations.1
Genotypic susceptibility to enfuvirtide was predicted with the 2007
ANRS resistance rules (www.hivfrenchresistance.org), and resis-
tance to a class was defined as resistance to at least one member of
the class.
The MacNemar test was used to compare the frequency of
mutations between T0, T1 and T2. Changes in the CD4 cell count
were compared between patients with and without specific mutations
by using the non-parametric Mann–Whitney test. Changes in
continuous variables were tested with the paired Wilcoxon test.
Results
Baseline characteristics of the 99 patients enrolled in the study
are summarized in Table 1. The median number of drugs
predicted to be effective, in addition to enfuvirtide, was 1
Table 1. Patients’ baseline characteristics
Characteristica All patients (n ¼ 99) Patients failing enfuvirtide (n ¼ 55)b
Male 88 (89%) 48 (87%)
Transmission group
homosexual 50 (51%) 21 (38%)
heterosexual 26 (26%) 19 (35%)
IV drug users 12 (12%) 9 (16%)
unknown 11 (11%) 6 (11%)
HIV-1 subtype B 85 (86%) 48 (87%)
Age 43 (38–49) 45 (37–51)
Duration of seropositivity (years) 12 (9–16) 12 (9–16)
Duration of antiretroviral therapy (years) 9 (8–11) 9 (8–11)
Number of previous antiretroviral drugs
PI 4 (4–5) 5 (5–7)
NRTI 6 (5–7) 6 (5–7)
NNRTI 1 (1–2) 1 (1–2)
HIV-1 plasma RNA (log10 copies/mL) 5.1 (4.6–6.6) 5.0 (4.5–5.5)
HIV-1 plasma RNA zenith (log10 copies/mL) 5.7 (5.3–5.9) 5.7 (5.4–5.9)
CD4 cell counts (cells/mm3) 72 (13–150) 83 (17–169)
Nadir CD4 count (cells/mm3) 16 (13–19) 15 (13–18)
Time from baseline to virological failure (weeks) 16 (13–19) 15 (13–18)
aValues are either number (percentage) or median (interquartile range).
bPatients with at least two samples during enfuvirtide failure.
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(range 0–5); 12, 46, 28 and 13 patients had viruses with resis-
tance to zero, one, two and three classes of antiretroviral drugs,
respectively. At baseline, four patients had viruses with a
single enfuvirtide resistance-associated mutation (V38A, V38E,
Q40Q/H and N42T) and two patients had viruses with two such
mutations (G36SþN43S and Q39RþN42S). Five positions
(42, 46, 54, 72 and 77) were polymorphic (.10%) in the HR-1
domain. In contrast, extensive polymorphism was observed in
12 positions (119, 121, 122, 125, 130, 135, 137, 147, 148, 151,
157 and 160) within the HR-2 domain.
Baseline characteristics of the 55 patients remaining on enfu-
virtide therapy despite virological failure were similar to those
of the whole population. Three of them had viruses bearing
mutations (V38A, Q40Q/H and N42T). Eight (15%), 21 (38%),
17 (31%) and 9 (16%) of these patients had viruses with resis-
tance to zero, one, two and three classes of antiretroviral drugs,
respectively.
The enfuvirtide resistance mutations selected between base-
line and virological failure are shown in Figure 1(a) for the
99 patients and in Figure 1(b) for the subgroup of 55 patients.
Six mutations (V38A/M, Q40H, N42T, N43D and L45M) were
selected in the HR-1 domain (all P, 0.02, MacNemar test). In
the subgroup of 55 patients, mutations G36D, Q40H, N42T,
N43D and L45M were selected between baseline and the
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Figure 1. Selection of mutations in the gp41 HR-1 domain. (a) Selection of mutations in the HR-1 domain of gp41 between baseline (T0) and initial
virological failure (T1) (n ¼ 99). (b) Selection of mutations in the HR-1 domain of gp41 between baseline (T0), initial virological failure (T1) and last
follow-up visit under enfuvirtide (T2) (n ¼ 55). Lowercase letters added to amino acid changes are as follows: a, mutations associated with enfuvirtide
resistance in both the IAS-USA 2006 and ANRS 2007 lists; b, mutations associated with enfuvirtide resistance in the IAS-USA 2006 list only; c, mutations
associated with enfuvirtide resistance in the ANRS 2007 list only. Asterisks in (a) indicate enfuvirtide resistance mutations significantly selected between
baseline (T0) and initial virological failure (T1) (P, 0.05). Asterisks in (b) indicate enfuvirtide resistance mutations significantly selected or deselected
between baseline (T0) and initial virological failure (T1) or the last follow-up visit on enfuvirtide (T2) (P, 0.05).
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follow-up sample on failing enfuvirtide therapy (all P , 0.02).
Mutations V38A/E/M reverted to the wild-type allele during
continued failing enfuvirtide therapy (P ¼ 0.02).
At initial virological failure, the median number of enfuvir-
tide resistance mutations was 1 (IQR: 0–1). The proportion of
patients with at least one enfuvirtide resistance mutation in the
gp41 gene was 71% (n ¼ 70) in the whole population of 99
patients and 73% (n ¼ 40) in the subgroup of 55 patients. The
corresponding rates were 75% (n ¼ 74) and 76% (n ¼ 42) based
on the ANRS 2007 resistance rules. No particular mutations in
the gp41 HR-2 domain were significantly selected between base-
line and initial virological failure or between baseline and the
final sample during continued failing enfuvirtide therapy,
although R122K and S138A tended to be selected in the HR-2
domain between baseline and continued failing enfuvirtide
therapy (P ¼ 0.063).
The median change in the HIV-1 viral load between baseline
and initial virological failure was 20.2 log copies/mL (IQR:
20.5 to 20.2) (P , 0.001). A median gain of 27 CD4
cells/mm3 (IQR: 0–82) was observed between baseline and
virological failure (P , 0.001). In the subgroup of 55 patients,
no significant change in the HIV-1 plasma RNA or in the CD4
cell count was observed between initial virological failure and
the follow-up sample during continued enfuvirtide therapy.
None of the mutations selected in the HR-1 domain at initial
virological failure was associated with the change in the CD4
cell count between baseline and initial virological failure.
However, between initial failure and the follow-up sample, the
presence of one or more enfuvirtide resistance mutations was
associated with a significant loss of CD4 cells (229 cells/mm3;
P ¼ 0.039). In particular, mutations V38A and N42T had a
negative impact on the CD4 cell count, with significant losses
of 39 and 32 cells/mm3, respectively (P ¼ 0.05). Moreover,
mutation V38M was associated with a significant increase in the
median HIV-1 viral load (þ0.4 log copies/mL). Interestingly,
patients with mutation G36D had an increase of 26 CD4
cells/mm3, whereas patients with G36 had a decline of 27 CD4
cells/mm3, but the difference was not significant (P ¼ 0.14).
Discussion
In one of the largest observational studies of enfuvirtide salvage
therapy, we have confirmed reports that amino acids 36–45 of
the HR1 domain are the main determinants of resistance to enfu-
virtide, as mutations in this region emerged in more than 70%
of our patients 3 months after enfuvirtide salvage therapy had
started to fail.
Interestingly, some patients had baseline mutations in the
HR-1 domain, despite being enfuvirtide naive prior to inclusion.
This has already been described in other studies.2,3
Mutations V38A/M, Q40H, N42T, N43D and L45M in the
HR-1 domain were significantly selected between baseline and
initial virological failure. The N42D mutation, listed in the
ANRS algorithm, was described in patients failing enfuvirtide
therapy and shown to confer decreased sensitivity to enfuvirtide
when present in site-directed mutants or in recombinant viruses.
In contrast, this mutation has not been noted in clinical isolates
with naturally occurring gp41 HR1 variations described in
enfuvirtide-naive patients.3,4 In our study, the N42D mutation
was selected between baseline and virological failure, but this
was not statistically significant. This raised the question of
whether to maintain this mutation in algorithms designed to
interpret enfuvirtide resistance.
Mutations V38A/E/M were most frequently selected (36%),
as reported previously.5 Cabrera et al.6 studied a small number
of heavily treated patients and found that mutations at positions
36 and 38 emerged rapidly (median 10 weeks) upon failure but
subsequently disappeared in most patients. We also found that
mutations V38A/E/M reverted to the wild type when the failing
enfuvirtide regimen was pursued, whereas mutations at position
36 did not revert, contrary to previous findings. In the study by
Cabrera et al.,6 the HR-1 domain was sequenced at weeks 4, 12,
24, 48 and 96, whereas we sequenced HR-1 only at baseline, at
initial virological failure and, in some patients, during failing
enfuvirtide therapy.
The gp41 HR2 domain was more polymorphic than HR1, as
reported elsewhere.5,7 Some mutations in HR-2 have been
suggested to contribute to enfuvirtide resistance,8,9 but no
specific HR-2 mutations emerged during our study. Further
studies are required to determine whether these mutations in the
HR-2 domain are involved in resistance to enfuvirtide.
Unlike Aquaro et al.,5 we observed no specific combinations
of mutations affecting both the HR1 and HR2 domains during
enfuvirtide treatment. Our findings do not confirm that the S138A
mutation in HR2 compensates for mutations at position 43.6
Contrary to Svicher et al.,10 we found that no specific patterns
of mutations in the HR-1 domain (e.g. V38A/E, Q40H þ L45M,
V38A þ T18A, V38AþN140I or V38A þ T18A þ N140I) were
associated with a CD4 cell count increment during the period of
our study. Mutation G36D was associated with an increase of 26
CD4 cells/mm3, compared with a decrease of 27 cells/mm3 in
patients with the wild-type allele, but the difference was not statis-
tically significant (P ¼ 0.14), and it is difficult to differentiate
between a lack of statistical power and a true phenomenon as this
has not been reported in other studies so far. In contrast, two
mutations, V38A and N42T, were associated with a loss of CD4
cells during follow-up after enfuvirtide failure. Our study and the
one of Svicher et al.10 are difficult to compare. Indeed, even if
both studies involved heavily treated patients, there were note-
worthy differences in baseline characteristics such as the CD4 cell
count, the CD4 nadir and plasma HIV-1 viral load. Furthermore,
gp41 was not sequenced at the same time points in the two
studies. Further studies are, therefore, required to clarify the
possible impact of gp41 mutations on the CD4 cell count. The
putative effect of gp41 mutations on CD4 count evolution was
described mainly after lengthy enfuvirtide selective pressure and
might not have to be taken into account as a therapeutic strategy
according to the new guidelines for antiretroviral use.
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